Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $242.50 million. The enterprise value is $227.33 million.
| Market Cap | 242.50M |
| Enterprise Value | 227.33M |
Important Dates
The next estimated earnings date is Monday, November 2, 2026, before market open.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 119.46 million shares outstanding. The number of shares has increased by 3.27% in one year.
| Current Share Class | 119.46M |
| Shares Outstanding | 119.46M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 3.56% |
| Owned by Institutions (%) | 14.43% |
| Float | 78.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.97 |
| Forward PS | 12,474.05 |
| PB Ratio | 11.26 |
| P/TBV Ratio | 21.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 1.56.
| Current Ratio | 1.34 |
| Quick Ratio | 1.20 |
| Debt / Equity | 1.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -179.10% and return on invested capital (ROIC) is -82.23%.
| Return on Equity (ROE) | -179.10% |
| Return on Assets (ROA) | -62.95% |
| Return on Invested Capital (ROIC) | -82.23% |
| Return on Capital Employed (ROCE) | -326.84% |
| Weighted Average Cost of Capital (WACC) | 11.02% |
| Revenue Per Employee | $197,107 |
| Profits Per Employee | -$1.58M |
| Employee Count | 56 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pyxis Oncology has paid $1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.24% in the last 52 weeks. The beta is 1.38, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -30.24% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 2.13 |
| Relative Strength Index (RSI) | 30.24 |
| Average Volume (20 Days) | 1,257,969 |
Short Selling Information
The latest short interest is 4.68 million, so 3.92% of the outstanding shares have been sold short.
| Short Interest | 4.68M |
| Short Previous Month | 3.97M |
| Short % of Shares Out | 3.92% |
| Short % of Float | 5.97% |
| Short Ratio (days to cover) | 5.05 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $11.04 million and -$88.73 million in losses. Loss per share was -$1.40.
| Revenue | 11.04M |
| Gross Profit | 8.65M |
| Operating Income | -89.71M |
| Pretax Income | -87.62M |
| Net Income | -88.73M |
| EBITDA | -85.53M |
| EBIT | -89.71M |
| Loss Per Share | -$1.40 |
Balance Sheet
The company has $33.00 million in cash and $17.83 million in debt, with a net cash position of $15.16 million or $0.13 per share.
| Cash & Cash Equivalents | 33.00M |
| Total Debt | 17.83M |
| Net Cash | 15.16M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 11.44M |
| Book Value Per Share | 0.18 |
| Working Capital | 9.26M |
Cash Flow
In the last 12 months, operating cash flow was -$67.91 million and capital expenditures -$9,000, giving a free cash flow of -$67.92 million.
| Operating Cash Flow | -67.91M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 4.18M |
| Net Borrowing | n/a |
| Free Cash Flow | -67.92M |
| FCF Per Share | -$0.57 |
Margins
| Gross Margin | 78.37% |
| Operating Margin | -812.74% |
| Pretax Margin | -793.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | -3.27% |
| Earnings Yield | -36.59% |
| FCF Yield | -28.01% |
Analyst Forecast
The average price target for Pyxis Oncology is $8.67, which is 327.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 327.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -3.96% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -15.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.71 |
| Piotroski F-Score | 2 |